Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
Joint Authors
Schwartz, Gary K.
Tap, William D.
D’Angelo, S. P.
Carvajal, R. D.
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-1, 1 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-06-09
Country of Publication
Egypt
No. of Pages
1
Main Subjects
Abstract EN
In the paper titled “Sarcoma Immunotherapy: Past Approaches and Future Directions” in the following sentence: “Currently, there is a phase II trial of a trivalent peptide vaccine to the gangliosides GD2, GD3, and GM2 in patients with sarcoma that have had solitary metastases excised (NCT00597272),” the corrected identifier should be NCT01141491.
American Psychological Association (APA)
D’Angelo, S. P.& Tap, William D.& Schwartz, Gary K.& Carvajal, R. D.. 2015. Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”. Complexity،Vol. 2015, no. 2015, pp.1-1.
https://search.emarefa.net/detail/BIM-1076065
Modern Language Association (MLA)
D’Angelo, S. P.…[et al.]. Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”. Complexity No. 2015 (2015), pp.1-1.
https://search.emarefa.net/detail/BIM-1076065
American Medical Association (AMA)
D’Angelo, S. P.& Tap, William D.& Schwartz, Gary K.& Carvajal, R. D.. Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”. Complexity. 2015. Vol. 2015, no. 2015, pp.1-1.
https://search.emarefa.net/detail/BIM-1076065
Data Type
Journal Articles
Language
English
Record ID
BIM-1076065
